Cases and Conversations™: Coordinating Care and Enhancing Outcomes in a New Era of Pancreatic Cancer Treatment

Activity Overview

Best practices in the treatment of pancreatic ductal adenocarcinoma (PDAC) are changing quickly. Comprehensive molecular profiling, combination chemotherapy, and KRAS-targeted therapies are moving toward routine practice. Advanced practice providers (APPs) and oncology nurses are central to coordinating molecular testing, managing treatment-related adverse events (AEs), and helping patients access new therapies.

This Cases and Conversations satellite symposium—presented at the 2026 Annual Journal of the Advanced Practitioner in Oncology Conference (JADPRO Live 2026) held from October 15 to 18, 2026, in Minneapolis, Minnesota—follows a patient with metastatic PDAC from diagnosis through disease progression. At each decision point, the expert faculty panel discusses practical strategies and personal experience with new standards of care, enabling nurses and APPs to apply these updates to their clinical practices.

This educational activity is an archive of the live virtual symposium held on October 15, 2026.

Target Audience

This educational activity is directed toward oncology APPs (nurse practitioners, physician assistants) and nurses, as well as clinical pharmacists involved in the care of patients with PDAC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify the appropriate molecular testing strategy, including the role of sequential DNA- and RNA-based next-generation sequencing, for patients with metastatic PDAC
• Apply regimen-specific AE prevention and management strategies across frontline PDAC chemotherapy options to sustain treatment duration
• Identify care team strategies for AE management, oral therapy adherence, and patient access coordination for KRAS-targeted therapies in PDAC

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.